{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:40:56Z","timestamp":1790401256951,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CTN HIV Trials Network"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13063-016-1454-6","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T13:28:25Z","timestamp":1469021305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Mary-Anne","family":"Doyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"issue":"1","key":"1454_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","volume":"6","author":"Global surveillance and control of hepatitis C","year":"1999","unstructured":"Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6(1):35\u201347.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1454_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/ncpendmet1027","volume":"5","author":"A Antonelli","year":"2009","unstructured":"Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5(1):26\u201334.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1454_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0168-8278(05)80631-2","volume":"21","author":"ME Allison","year":"1994","unstructured":"Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes in a cirrhotic population. J Hepatol. 1994;21:1135\u20139.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"1454_CR4","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/S0168-8278(12)60007-5","volume":"56","author":"E Bugianesi","year":"2012","unstructured":"Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol. 2012;56 Suppl 1:S56\u201365.","journal-title":"J Hepatol"},{"issue":"4","key":"1454_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/gut.2005.069674","volume":"55","author":"MJ Walsh","year":"2006","unstructured":"Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55(4):529\u201335.","journal-title":"Gut"},{"issue":"6","key":"1454_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jhep.2011.03.010","volume":"55","author":"P Deltenre","year":"2011","unstructured":"Deltenre P, Louvet A, Lemoine M, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol. 2011;55(6):1187\u201394.","journal-title":"J Hepatol"},{"issue":"12","key":"1454_CR7","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s10620-008-0683-2","volume":"54","author":"HM Elgouhari","year":"2009","unstructured":"Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci. 2009;54(12):2699\u2013705.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"1454_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2036.2011.04716.x","volume":"34","author":"M Eslam","year":"2011","unstructured":"Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34(3):297\u2013305.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1454_CR9","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/j.1572-0241.2006.00835.x","volume":"101","author":"N Taura","year":"2006","unstructured":"Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol. 2006;101(12):2752\u20139.","journal-title":"Am J Gastroenterol"},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","volume":"125","author":"J Hui","year":"2003","unstructured":"Hui J, Sud A, Farrell G, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology. 2003;125:1695\u2013704.","journal-title":"Gastroenterology"},{"issue":"18","key":"1454_CR11","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3748\/wjg.v16.i18.2265","volume":"16","author":"CH Hung","year":"2010","unstructured":"Hung CH, Wang JH, Hu TH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol. 2010;16(18):2265\u201371.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1454_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/00007890-200109270-00015","volume":"72","author":"S Baid","year":"2001","unstructured":"Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72(6):1066\u201372.","journal-title":"Transplantation"},{"issue":"2","key":"1454_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1086\/599371","volume":"49","author":"AA Butt","year":"2009","unstructured":"Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49(2):225\u201332.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1454_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/gut.2010.236158","volume":"61","author":"AJ Thompson","year":"2012","unstructured":"Thompson AJ, Patel K, Chuang WL, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2\/3. Gut. 2012;61(1):128\u201334.","journal-title":"Gut"},{"key":"1454_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425\u201356.","journal-title":"Annu Rev Pathol"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/gut.2010.219089","volume":"59","author":"R Moucari","year":"2010","unstructured":"Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, et al. Danoprevir, an HCV NS3\/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut. 2010;59:1694\u20138.","journal-title":"Gut"},{"issue":"6","key":"1454_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"6","key":"1454_CR18","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/j.ijid.2012.02.004","volume":"16","author":"JW Yu","year":"2012","unstructured":"Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. Int J Infect Dis. 2012;16(6):e436\u201341.","journal-title":"Int J Infect Dis"},{"issue":"8","key":"1454_CR19","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1210\/jc.2010-2415","volume":"96","author":"G Nkontchou","year":"2011","unstructured":"Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011;96(8):2601\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1454_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ajg.2011.384","volume":"107","author":"SW Lai","year":"2012","unstructured":"Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107(1):46\u201352.","journal-title":"Am J Gastroenterol"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","volume":"56","author":"G Baffy","year":"2012","unstructured":"Baffy G, Brunt E, Caldwell S. Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. J Hepatol. 2012;56:1384\u201391.","journal-title":"J Hepatol"},{"key":"1454_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/jcp.22824","volume":"227","author":"JY Lim","year":"2012","unstructured":"Lim JY, Oh MA, Kim WH, Sohn HY, Park S. AMP-activated protein kinase inhibits TGF-\u03b2-induced fibrogenic responses to hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol. 2012;227:1081\u201389.","journal-title":"J Cell Physiol"},{"key":"1454_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1053\/j.gastro.2008.01.005","volume":"134","author":"W Lin","year":"2008","unstructured":"Lin W, Weinberg EM, Tai AW, et al. HIV increases HCV replication in a TGF-B1-dependent manner. Gastroenterology. 2008;134:803\u201311.","journal-title":"Gastroenterology"},{"key":"1454_CR24","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1210\/jc.2011-1875","volume":"96","author":"V Popov","year":"2011","unstructured":"Popov V, Lim JK. Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis. JCEM. 2011;96:2398\u20132400.","journal-title":"JCEM"},{"key":"1454_CR25","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1002\/hep.1840360710","volume":"36","author":"HB El-Serag","year":"2002","unstructured":"El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74\u201383.","journal-title":"Hepatology"},{"key":"1454_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1600-0676.1986.tb00279.x","volume":"6","author":"YF Liaw","year":"1986","unstructured":"Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver. 1986;6:133\u20137.","journal-title":"Liver"},{"key":"1454_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1440-1746.2007.04898.x","volume":"22","author":"TM Chen","year":"2007","unstructured":"Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669\u201375.","journal-title":"J Gastroenterol Hepatol"},{"key":"1454_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jhep.2005.03.019","volume":"43","author":"AM Bisceglie Di","year":"2005","unstructured":"Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434\u201341.","journal-title":"J Hepatol"},{"key":"1454_CR29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jhep.2009.07.008","volume":"51","author":"A Grasso","year":"2009","unstructured":"Grasso A, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol. 2009;51:984\u201390.","journal-title":"J Hepatol"},{"key":"1454_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bjid.2013.02.009","volume":"17","author":"MP Laurito","year":"2013","unstructured":"Laurito MP, Parise ER. Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis. Braz J Infect Dis. 2013;17:555\u201363.","journal-title":"Braz J Infect Dis"},{"key":"1454_CR31","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2169\/internalmedicine.52.0992","volume":"52","author":"Y Kawaguchi","year":"2013","unstructured":"Kawaguchi Y, Mizuta T, Eguchi Y, Sakurai E, Motomura Y, Isoda H, et al. Whole-body insulin resistance is associated with elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. Intern Med. 2013;52:2393\u2013400.","journal-title":"Intern Med"},{"key":"1454_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-0035-1550056","volume":"35","author":"M Pinzani","year":"2015","unstructured":"Pinzani M. Liver fibrosis in the post-HCV era. Sem Liv Dis. 2015;35:157\u201365.","journal-title":"Sem Liv Dis"},{"key":"1454_CR33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","volume":"19","author":"KP Batts","year":"1995","unstructured":"Batts KP, Ludwig J. Chronic hepatitis an update on terminology and reporting. Am J Surg Pathol. 1995;19:1409\u201317.","journal-title":"Am J Surg Pathol"},{"key":"1454_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1471-2334-10-183","volume":"10","author":"SH Sheth","year":"2010","unstructured":"Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010;10:183.","journal-title":"BMC Infect Dis"},{"key":"1454_CR35","first-page":"CD002967","volume":"1","author":"S Salpeter","year":"2006","unstructured":"Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes. Cochrane Database Syst Rev. 2006;1:CD002967.","journal-title":"Cochrane Database Syst Rev"},{"key":"1454_CR36","unstructured":"Valeant Canada LP. PrGlycol\u00ae Product Monograph. Revision date December 05, 2008."},{"issue":"2","key":"1454_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.antiviral.2009.04.002","volume":"83","author":"E Ogawa","year":"2009","unstructured":"Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009;83(2):127\u201334.","journal-title":"Antiviral Res"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-016-1454-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1454-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T05:07:03Z","timestamp":1600924023000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-016-1454-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1186\/s13063-016-1454-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,20]]},"article-number":"331"}}